Gilead's research team, led by virologist Tomas Cihlar, has developed a long-acting injectable prevention method that could reshape HIV prevention strategies. The innovation marks a significant shift from daily oral medication regimens that require consistent adherence.
Cihlar's team focused on creating formulations that remain effective in the body for extended periods, reducing the burden on patients to remember daily doses. Long-acting injectables address one of the primary barriers to prevention: medication adherence. Studies show that missing doses compromises protection, particularly among populations with inconsistent access to healthcare or those managing competing health priorities.
The Gilead approach centers on cabotegravir and rilpivirine, antiretrovirals administered as injections every one or two months. Clinical trials demonstrated that monthly injections matched or exceeded the efficacy of daily oral PrEP (pre-exposure prophylaxis) in preventing HIV acquisition. The method works by maintaining therapeutic drug levels in the bloodstream continuously, eliminating the timing issues associated with daily pills.
This development matters for global HIV prevention. The World Health Organization estimates that nearly 40 million people live with HIV, with prevention gaps particularly pronounced in sub-Saharan Africa and among key populations including men who have sex with men. Adherence challenges persist even among motivated individuals, making long-acting options essential for closing prevention gaps.
Cihlar's research built on decades of virology work examining how HIV integrates into cells and develops resistance. The team's focus on durability rather than frequency represents a patient-centered approach grounded in real-world behavior patterns.
Regulatory approval has already occurred in several countries, with additional approvals pending. Scaling production and ensuring equitable access remain open questions. Cost and distribution infrastructure in resource-limited settings will determine whether this innovation reaches populations bearing the highest HIV burden.
The long-acting injectable approach doesn't